Peginterferon-α2a (40 kDa) for chronic hepatitis C

Author： Hadziyannis Stephanos J   Papatheodoridis George V  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.4, 2003-04, pp. : 541-551

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peginterferon-α2a in the treatment of chronic hepatitis C

By Akimov Sergey   Adeyemi Oluwatoyin M  

Future Virology, Vol. 1, Iss. 6, 2006-11 ,pp. : 689-701

Future Medicine

Access to resources Recommend Favorite

Peginterferon-α-2a (40 kD) Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C Mono-Infection

By Keam Susan J.   Cvetković Risto S.  

Drugs, Vol. 68, Iss. 9, 2008-01 ,pp. : 1273-1317

Adis International

Access to resources Recommend Favorite

Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy

By Modi Marlene   Martin Nancy   Heathcote Jenny E   Nieforth Keith   Zeuzem Stefan  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 12, 2001-12 ,pp. : 2201-2213

Informa Healthcare

Access to resources Recommend Favorite

Peginterferon-α-2a (40kD): A Review of its Use in the Management of Patients with Chronic Hepatitis B

By Robins Gayle W.   Scott Lesley J.   Keating Gillian M.  

Drugs, Vol. 65, Iss. 6, 2005-01 ,pp. : 809-825

Adis International

Access to resources Recommend Favorite

Peginterferon-α-2a (40 kD): A Review of its Use in Chronic Hepatitis B

By Keating Gillian M.  

Drugs, Vol. 69, Iss. 18, 2009-12 ,pp. : 2633-2660

Adis International

Access to resources Recommend Favorite